Frequently Asked Questions
The market is segmented based on , By Product Type (Genomics Biomarker, Proteomics Biomarker, Imaging Biomarker, Metabolomics Biomarker, Others), Indication (Spinal Muscular Atrophy, Parkinson's Disease, Schizophrenia, Huntington's Disease, Alzheimer's Disease, Depression, Multiple Sclerosis), Imaging Techniques (Transcranial Magnetic Stimulation, Diffusion Tensor Imaging, Conventional Structural MRI, Functional Magnetic Resonance Imaging, Positron Emission Tomography), Services (Sample Preparation, Assay Development, Biomarker Validation and Testing), End- User (Clinical Diagnostics, Pharmaceutical and Biotechnology Companies, Research Organizations) – Industry Trends and Forecast to 2030.
.
The Global Neurological Biomarkers Market size was valued at USD 6.92 USD Billion in 2022.
The Global Neurological Biomarkers Market is projected to grow at a CAGR of 13.4% during the forecast period of 2023 to 2030.
The major players operating in the market include Thermo Fisher Scientific, QIAGEN, Agilent Technologies, McKesson Corporation, R1 RCM , F. Hoffmann La Roche , BioRad Laboratories, BGI, Quanterix, bioMérieux , Neurosteer , Advanced Brain Monitoring .
The market report covers data from the U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
